Gateway Investment Advisers LLC Invests $666,000 in Charles River Laboratories International, Inc. $CRL

Gateway Investment Advisers LLC acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,338 shares of the medical research company’s stock, valued at approximately $666,000.

Other institutional investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its holdings in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the period. Empowered Funds LLC purchased a new position in Charles River Laboratories International during the 1st quarter valued at $418,000. American Century Companies Inc. grew its position in Charles River Laboratories International by 41.9% in the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 1,616 shares during the last quarter. Brown Advisory Inc. increased its stake in Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the period. Finally, California Public Employees Retirement System increased its stake in Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $177.96 on Friday. The firm has a market cap of $8.78 billion, a P/E ratio of -47.33, a P/E/G ratio of 2.15 and a beta of 1.44. The company has a current ratio of 1.36, a quick ratio of 1.02 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 12 month low of $132.58 and a 12 month high of $228.88. The stock’s fifty day moving average price is $170.79 and its 200-day moving average price is $183.34.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same period in the prior year, the firm earned $2.34 earnings per share. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reported Q1 EPS of $2.06, ahead of the $1.96 consensus, and revenue of $995.8 million, also above estimates. Reuters article
• Positive Sentiment: Reuters noted steady demand for drug discovery and development services, suggesting the core business is stabilizing. Reuters article
• Neutral Sentiment: Management reaffirmed full-year 2026 EPS guidance of $10.80 to $11.30, which is in line with expectations but not a major upside surprise. Earnings release and transcript
• Negative Sentiment: Investors appear concerned that margin compression and weak organic growth may offset the earnings beat, which helps explain the stock’s weakness. Zacks article
• Negative Sentiment: One recent analyst note downgraded CRL to Sell, citing a strong share rally, muted near-term growth, and longer-term risks. Seeking Alpha article

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research note on Friday. Barclays lifted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday. Evercore reissued an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a research note on Friday. Finally, Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $205.86.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.